Humacyte Inc HUMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies
-
Humacyte's Bioengineered Blood Vessel Hits Primary Endpoint in Phase 3 Trial
-
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
-
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
-
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
-
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
-
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
-
Humacyte Shares Climb on Symvess ECAT Listing
Trading Information
- Previous Close Price
- $0.97
- Day Range
- $0.90–0.96
- 52-Week Range
- $0.55–2.83
- Bid/Ask
- $0.92 / $0.92
- Shares Outstanding
- 269.64M
- Market Cap
- $247.23M
- Volume/Avg
- 5M / 8M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 91.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 184
- Website
- https://www.humacyte.com
Valuation
|
Metric
|
HUMA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 20.15 |
Price/Sales | 91.44 |
Price/Cash Flow | — |
Price/Earnings
HUMA
Financial Strength
|
Metric
|
HUMA
|
|---|---|
Quick Ratio | 3.03 |
Current Ratio | 3.93 |
Interest Coverage | −8.49 |
Quick Ratio
HUMA
Profitability
|
Metric
|
HUMA
|
|---|---|
Return on Assets (Normalized) | −90.13% |
Return on Equity (Normalized) | −1,115.46% |
Return on Invested Capital (Normalized) | −214.08% |
Return on Assets
HUMA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Jmjt | — | |||
| Athersys Inc
ATHXQ
| — | Kft | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Psckwnsm | Wbzrpc | $116B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rfwvpfb | Rhdyfh | $64B | |||
| argenx SE
ARGNF
| — | Spd | $56B | |||
| argenx SE ADR
ARGX
| Gxzzwftnv | Xbrlz | $56B | |||
| UCB SA
UCBJF
| — | Cbs | $56B | |||
| UCB SA ADR
UCBJY
| — | Bdvp | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ymwnbnlc | Syvbnr | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| Cdzbynlv | Rlxv | $30B |
United States